The CSIR seeks information on market capabilities and cost estimates for a feasibility study to establish a multipurpose pharmaceutical manufacturing facility. Interested parties should provide insights into project scope, methodologies, and indicative timelines.
The Council for Scientific and Industrial Research (CSIR) is requesting information to support a feasibility study aimed at developing a national, open-access pharmaceutical and vaccine manufacturing facility. This facility will enhance South Africa's capacity to produce clinical and commercial pharmaceutical products locally, addressing the current limitations in Good Manufacturing Practice (GMP) infrastructure. The study will assess the scope, methodologies, and expertise required to ensure the facility meets the needs of public and private developers, research institutions, and emerging manufacturers.
Respondents are expected to provide high-level insights into the feasibility study's workstreams, including manufacturing capabilities for vaccines, biologics, and small-molecule active pharmaceutical ingredients (APIs). The CSIR aims to understand the potential costs, timelines, and necessary expertise for this project, which will be structured to align with the National Treasury Budget Facility for Infrastructure. This initiative is crucial for advancing local pharmaceutical production and improving public health outcomes across the region.
This tender is suitable for consulting firms, engineering companies, and multidisciplinary consortia with experience in pharmaceutical manufacturing, regulatory compliance, and feasibility studies in the healthcare sector.
Answer a few questions — by voice, chat or a short form — and your official quote arrives as a PDF you can circulate for sign-off, ready to accept online. One fixed annual figure for your whole bid team.